07:00 , Oct 15, 2012 |  BioCentury  |  Strategy

At home with Servier

Rather than follow in the footsteps of other foundation-backed mid-size European pharmas that have largely concentrated on a single therapeutic area and looked to new markets for growth, Servier has determined its path to sustainability...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Company News

Cortex Pharmaceuticals, Servier deal

Servier exercised an option from Cortex to license exclusive, worldwide rights to develop and commercialize CX1632. Cortex will receive $2 million up front, and is eligible for milestones and royalties. Servier paid Cortex $1...
00:46 , Oct 7, 2011 |  BC Extra  |  Company News

Servier exercises option for Cortex's CX1632

Servier (Neuilly-sur-Seine, France) exercised an option from Cortex Pharmaceuticals Inc. (OTCBB:CORX) to license exclusive, worldwide rights to develop and commercialize CX1632. Cortex will receive $2 million up front, and is eligible for milestones and royalties....
07:00 , Jun 20, 2011 |  BC Week In Review  |  Company News

Cortex Pharmaceuticals, Servier deal

Servier paid Cortex $1 million for an option to purchase worldwide rights to jointly discovered CX1632 ( S47445) as well as a sub-license of Cortex's rights to all indications licensed from the University of...
07:00 , Mar 21, 2011 |  BC Week In Review  |  Company News

Cortex Pharmaceuticals, Valeant Pharmaceutical International Inc. deal

Cortex reacquired a portfolio of Ampakines for respiratory depression and related IP from Valeant. Valeant, which gained the assets through last year's merger with Biovail Corp., discontinued the Ampakine program last November after it...
00:45 , Mar 17, 2011 |  BC Extra  |  Company News

Cortex reacquires Ampakines from Valeant

Cortex Pharmaceuticals Inc. (OTCBB:CORX) reacquired a portfolio of Ampakines for respiratory depression and related IP from Valeant Pharmaceuticals International Inc. (NYSE:VRX; TSX:VRX). Valeant, which gained the assets through last year's merger with Biovail Corp., discontinued...
08:00 , Dec 13, 2010 |  BioCentury  |  Strategy

Unwinding Biovail's Deals

Unwinding Biovail's Deals Deal date Partner Product Product description Product status Deal status Deal terms Jun-10 Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) Istradefylline Adenosine A2A...
08:00 , Nov 8, 2010 |  BC Week In Review  |  Clinical News

CX717: Development discontinued

Valeant said it will not pursue further development of BVF-007 to treat respiratory depression. Valeant, which gained the Ampakine through its merger with Biovail Corp. this year, said the program did not fit with...
08:00 , Nov 8, 2010 |  BioCentury  |  Finance

Regulatory milestones

Regulatory milestones Adventrx Pharmaceuticals Inc. (NYSE-A:ANX) lost $0.03 to $2.07 last week after resubmitting an NDA to FDA for Exelbine vinorelbine injectable emulsion to treat non-small cell lung cancer (NSCLC). The company said the submission included...
00:26 , Nov 5, 2010 |  BC Extra  |  Top Story

Valeant continues to carve up Biovail

Valeant Pharmaceuticals International Inc. (NYSE:VRX; TSX:VRX) will reduce headcount by 29% and discontinue two additional development programs as part of its ongoing restructuring following its merger with Biovail Corp. in September. Valeant, which has already...